Thomas Cerny
Dealing with ethical dilemmas in oncological communication involving issues of culture and autonomy
Strasser F, Cerny T. Dealing with ethical dilemmas in oncological communication involving issues of culture and autonomy. Oncology (Williston Park, N.Y.) 2012; 26:56, 62, 64.
Jan 1, 2012Dealing with ethical dilemmas in oncological communication involving issues of culture and autonomy
Jan 1, 2012Oncology (Williston Park, N.Y.) 2012; 26:56, 62, 64
Strasser Florian, Cerny Thomas
Surgical resection of isolated adrenal metastases in patients with non-small cell lung cancer: a single-institution experience and review of the literature
Bastian S, Clerici T, Neuweiler J, Cerny T, Früh M. Surgical resection of isolated adrenal metastases in patients with non-small cell lung cancer: a single-institution experience and review of the literature. Onkologie 2011; 34:665-70.
Nov 21, 2011Surgical resection of isolated adrenal metastases in patients with non-small cell lung cancer: a single-institution experience and review of the literature
Nov 21, 2011Onkologie 2011; 34:665-70
Bastian Sara, Clerici Thomas, Neuweiler Jörg, Cerny Thomas, Früh Martin
Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group
Borchmann P, Paulus U, Smardova L, Huber C, Dörken B, Nerl C, Krause S, Mueller R, Fuchs M, Rank A, Greil R, Haverkamp H, Diehl V, Cerny T, Markova J, Ho A, Eich H, Mueller-Hermelink H, Kanz L, Engert A. Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group. J Clin Oncol 2011; 29:4234-42.
Oct 11, 2011Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group
Oct 11, 2011J Clin Oncol 2011; 29:4234-42
Borchmann Peter, Paulus Ursula, Smardova Lenka, Huber Christoph, Dörken Bernd, Nerl Christoph, Krause Stefan W, Mueller Rolf-Peter, Fuchs Michael, Rank Andreas, Greil Richard, Haverkamp Heinz, Diehl Volker, Cerny Thomas, Markova Jana, Ho Anthony D, Eich Hans-Theodor, Mueller-Hermelink Hans Konrad, Kanz Lothar, Engert Andreas
Athrombogenic coating of long-term venous catheter for cancer patients: a prospective, randomised, double-blind trial
Hitz F, Klingbiel D, Omlin A, Riniker S, Zerz A, Cerny T. Athrombogenic coating of long-term venous catheter for cancer patients: a prospective, randomised, double-blind trial. Ann Hematol 2011; 91:613-20.
Sep 29, 2011Athrombogenic coating of long-term venous catheter for cancer patients: a prospective, randomised, double-blind trial
Sep 29, 2011Ann Hematol 2011; 91:613-20
Hitz Felicitas, Klingbiel Dirk, Omlin Aurelius, Riniker Salome, Zerz Andreas, Cerny Thomas
Phase I dose-finding study of vandetanib in combination with gemcitabine in locally advanced unresectable or metastatic pancreatic adenocarcinoma
Saletti P, Sessa C, De Dosso S, Cerny T, Renggli V, Köberle D. Phase I dose-finding study of vandetanib in combination with gemcitabine in locally advanced unresectable or metastatic pancreatic adenocarcinoma. Oncology 2011; 81:50-4.
Sep 15, 2011Phase I dose-finding study of vandetanib in combination with gemcitabine in locally advanced unresectable or metastatic pancreatic adenocarcinoma
Sep 15, 2011Oncology 2011; 81:50-4
Saletti Piercarlo, Sessa Cristiana, De Dosso Sara, Cerny Thomas, Renggli Verena, Köberle Dieter
Langerhans cell histiocytosis with central nervous system involvement-complete response to 2-chlorodeoxyadenosine after failure of tyrosine kinase inhibitor therapies with sorafenib and imatinib
Baumann M, Cerny T, Sommacal A, Köberle D. Langerhans cell histiocytosis with central nervous system involvement-complete response to 2-chlorodeoxyadenosine after failure of tyrosine kinase inhibitor therapies with sorafenib and imatinib. Hematol Oncol 2011
Jul 5, 2011Langerhans cell histiocytosis with central nervous system involvement-complete response to 2-chlorodeoxyadenosine after failure of tyrosine kinase inhibitor therapies with sorafenib and imatinib
Jul 5, 2011Hematol Oncol 2011
Baumann Michael, Cerny Thomas, Sommacal Andreas, Köberle Dieter
Novel prognostic markers in the serum of patients with castration-resistant prostate cancer derived from quantitative analysis of the pten conditional knockout mouse proteome
Kaelin M, Krek W, Aebersold R, Cerny T, Templeton A, Wild P, Powles T, Fankhauser N, Schiess R, Cima I, Gillessen Sommer S. Novel prognostic markers in the serum of patients with castration-resistant prostate cancer derived from quantitative analysis of the pten conditional knockout mouse proteome. Eur Urol 2011; 60:1235-43.
Jun 29, 2011Novel prognostic markers in the serum of patients with castration-resistant prostate cancer derived from quantitative analysis of the pten conditional knockout mouse proteome
Jun 29, 2011Eur Urol 2011; 60:1235-43
Kaelin Martin, Krek Wilhelm, Aebersold Ruedi, Cerny Thomas, Templeton Arnoud, Wild Peter, Powles Tom, Fankhauser Niklaus, Schiess Ralph, Cima Igor, Gillessen Sommer Silke
Extrapulmonary small cell carcinoma: An indication for prophylactic cranial irradiation? A single center experience
Früh M, Kacsir B, ess s, Cerny T, Rodriguez R, Plasswilm L. Extrapulmonary small cell carcinoma: An indication for prophylactic cranial irradiation? A single center experience. Strahlenther Onkol 2011; 187:561-7.
Jun 27, 2011Extrapulmonary small cell carcinoma: An indication for prophylactic cranial irradiation? A single center experience
Jun 27, 2011Strahlenther Onkol 2011; 187:561-7
Früh Martin, Kacsir Bela, ess silvia, Cerny Thomas, Rodriguez Regulo, Plasswilm Ludwig
Cancer genetics-guided discovery of serum biomarker signatures for diagnosis and prognosis of prostate cancer
Cima I, Wyler S, Zehetner J, Jochum W, Buhmann J, Cerny T, Moch H, Gillessen Sommer S, Aebersold R, Leippold T, Fuchs T, Schubert O, Schiess R, Wild P, Kaelin M, Schüffler P, Lange V, Picotti P, Ossola R, Templeton A, Krek W. Cancer genetics-guided discovery of serum biomarker signatures for diagnosis and prognosis of prostate cancer. Proc Natl Acad Sci USA 2011; 108:3342-7.
Feb 7, 2011Cancer genetics-guided discovery of serum biomarker signatures for diagnosis and prognosis of prostate cancer
Feb 7, 2011Proc Natl Acad Sci USA 2011; 108:3342-7
Cima Igor, Wyler Stephen, Zehetner Jens, Jochum Wolfram, Buhmann Joachim, Cerny Thomas, Moch Holger, Gillessen Sommer Silke, Aebersold Ruedi, Leippold Thomas, Fuchs Thomas, Schubert Olga, Schiess Ralph, Wild Peter, Kaelin Martin, Schüffler Peter, Lange Vinzenz, Picotti Paola, Ossola Reto, Templeton Arnoud, Krek Wilhelm
Cardiac manifestations of extracardiac tumours - from an oncologist's perspective
Hagner N, Cerny T. Cardiac manifestations of extracardiac tumours - from an oncologist's perspective. Cardiovascular Medicine 2011; 14:199-204.
Jan 1, 2011Cardiac manifestations of extracardiac tumours - from an oncologist's perspective
Jan 1, 2011Cardiovascular Medicine 2011; 14:199-204
Hagner Nicole, Cerny Thomas
[New treatments of malignant lymphoma--a review]
Mark M, Cerny T. [New treatments of malignant lymphoma--a review]. Ther Umsch 2010; 67:537-43.
Oct 1, 2010[New treatments of malignant lymphoma--a review]
Oct 1, 2010Ther Umsch 2010; 67:537-43
Mark Michael, Cerny Thomas
Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine
Perotti A, Haluska F, Rivera V, Berk L, Corradino I, Marsoni S, Albanell J, Rojo F, Cresta S, Cerny T, Maur M, Capri G, Viganò L, Hess D, Sessa C, Locatelli A, Gianni L. Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine. J Clin Oncol 2010; 28:4554-61.
Sep 20, 2010Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine
Sep 20, 2010J Clin Oncol 2010; 28:4554-61
Perotti Antonella, Haluska Frank, Rivera Victor M, Berk Lori, Corradino Irene, Marsoni Silvia, Albanell Joan, Rojo Federico, Cresta Sara, Cerny Thomas, Maur Michela, Capri Giuseppe, Viganò Lucia, Hess Dagmar, Sessa Cristiana, Locatelli Alberta, Gianni Luca
Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98
Martinelli G, Zucca E, Dietrich P, Lohri A, Vorobiof D, Heizmann M, Stahel R, Stupp R, Okkinga E, Bassi S, Hess U, Cerny T, Utiger U, Schmitz S, Ghielmini M. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. J Clin Oncol 2010; 28:4480-4.
Aug 9, 2010Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98
Aug 9, 2010J Clin Oncol 2010; 28:4480-4
Martinelli Giovanni, Zucca Emanuele, Dietrich Pierre-Yves, Lohri Andreas, Vorobiof Daniel, Heizmann Marc, Stahel Rolf, Stupp Roger, Okkinga Emmie, Bassi Simona, Hess Urs, Cerny Thomas, Utiger Urs, Schmitz Shu-Fang Hsu, Ghielmini Michele
Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial
Jörger M, Huitema A, Krähenbühl S, Schellens J, Cerny T, Reni M, Zucca E, Cavalli F, Ferreri A. Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial. Br J Cancer 2010; 102:673-7.
Feb 2, 2010Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial
Feb 2, 2010Br J Cancer 2010; 102:673-7
Jörger Markus, Huitema A D R, Krähenbühl S, Schellens J H M, Cerny Thomas, Reni M, Zucca E, Cavalli F, Ferreri A J M
Erstes Symposium für Integrative Onkologie und Forschung in der Schweiz
Wolf U, Heusser P, Cerny T, Schlaeppi M. Erstes Symposium für Integrative Onkologie und Forschung in der Schweiz. Swiss Journal of Integrative Medicine 2010:34-35.
Jan 18, 2010Erstes Symposium für Integrative Onkologie und Forschung in der Schweiz
Jan 18, 2010Swiss Journal of Integrative Medicine 2010:34-35
Wolf Ursula, Heusser Peter, Cerny Thomas, Schlaeppi Marc
Development of symptom assessments utilising item response theory and computer-adaptive testing--a practical method based on a systematic review
Walker J, Böhnke J, Cerny T, Strasser F. Development of symptom assessments utilising item response theory and computer-adaptive testing--a practical method based on a systematic review. Critical reviews in oncology/hematology 2010; 73:47-67.
Jan 1, 2010Development of symptom assessments utilising item response theory and computer-adaptive testing--a practical method based on a systematic review
Jan 1, 2010Critical reviews in oncology/hematology 2010; 73:47-67
Walker Jochen, Böhnke Jan R, Cerny Thomas, Strasser Florian
The role of pemetrexed in advanced non small-cell lung cancer: special focus on pharmacology and mechanism of action
Jörger M, Omlin A, Cerny T, Früh M. The role of pemetrexed in advanced non small-cell lung cancer: special focus on pharmacology and mechanism of action. Current drug targets 2010; 11:37-47.
Jan 1, 2010The role of pemetrexed in advanced non small-cell lung cancer: special focus on pharmacology and mechanism of action
Jan 1, 2010Current drug targets 2010; 11:37-47
Jörger Markus, Omlin Aurelius, Cerny Thomas, Früh Martin
Long term follow up of patients with follicular lymphoma receiving single agent rituximab at 2 different schedules in trial SAKK 35/98
Martinelli G, Zucca E, Dietrich P, Lohri A, Vorobiof H, Heizmann M, Stahel R, Stupp R, Okkinga E, Hess U, Cerny T, Utiger U, Schmitz S, Ghielmini M. Long term follow up of patients with follicular lymphoma receiving single agent rituximab at 2 different schedules in trial SAKK 35/98. J Clin Oncol 2010; 28:4480-4484.
Jan 1, 2010Long term follow up of patients with follicular lymphoma receiving single agent rituximab at 2 different schedules in trial SAKK 35/98
Jan 1, 2010J Clin Oncol 2010; 28:4480-4484
Martinelli G, Zucca E, Dietrich P Y, Lohri A, Vorobiof H, Heizmann M, Stahel R, Stupp R, Okkinga E, Hess Urs, Cerny Thomas, Utiger U, Schmitz S F, Ghielmini M
Premature deaths in Switzerland from 1995-2006: causes and trends
Savidan A, Junker C, Cerny T, Ess S. Premature deaths in Switzerland from 1995-2006: causes and trends. Swiss Med Wkly 2010; 24:140.
Jan 1, 2010Premature deaths in Switzerland from 1995-2006: causes and trends
Jan 1, 2010Swiss Med Wkly 2010; 24:140
Savidan A, Junker C, Cerny Thomas, Ess S
Lung Cancer in the Canton of St. Gallen, Eastern Switzerland:
Cerny D, Cerny T, ess s, D'Addario G, Früh M. Lung Cancer in the Canton of St. Gallen, Eastern Switzerland:. Onkologie 2009; 32:569-73.
Oct 13, 2009Lung Cancer in the Canton of St. Gallen, Eastern Switzerland:
Oct 13, 2009Onkologie 2009; 32:569-73
Cerny David, Cerny Thomas, ess silvia, D'Addario G, Früh Martin